

### WAVE 1 BULLETIN

### **JUNE 2020**

# Key findings from the 'Australians' Drug Use: Adapting to Pandemic Threats' (ADAPT) Study

### BACKGROUND

### What are the aims of the ADAPT Study?

The <u>Australians' Drug Use: Adapting to Pandemic</u> <u>Threats (ADAPT) Study is exploring the short and</u> <u>long-term impact of the COVID-19 pandemic on</u> the experiences of <u>Australians who use illicit</u> <u>drugs</u>. Findings will be used to ensure drug-related issues during COVID-19 are better understood and more accurately represented, so as to better inform <u>drug treatment and harm reduction in</u> <u>Australia</u>.

### What does the ADAPT Study involve?

Australians who regularly (i.e. at least once a month) used illicit drugs in 2019 were invited to complete an online survey initially and follow-up surveys in 2 months, 4 months, 6 months, 12 months, 2 years and 3 years. Participants could opt to complete the Wave 1 survey only.


### What have we found so far?


The information below outlines findings from the **702 eligible participants** who completed the Wave 1 survey from **29 April to 15 June 2020**.



The ADAPT sample mostly comprised young, well-educated (62% completed tertiary/university qualification) capital city dwellers, although notably one-quarter (25%) of participants reported living in regional/rural/remote areas.

Participants ranged in age from 18-67, with a median age of 25 years. Similar proportions of men and women took part, with 4% of participants identifying as nonbinary.





Most participants (86%) reported that they had not experienced any COVID-19 symptoms, nor been tested, at the time of interview. 10% had been tested, with no participants reporting that they had tested positive (<1% awaiting results).

### **10%** of the sample were tested for COVID-19

**Citation:** Sutherland, R., Baillie, G., Memedovic, S., Hammoud, M., Barratt, M., Bruno, R., Dietze, P., Ezard, N., Salom, C., Degenhardt, L., Hughes, C. & Peacock, A. (2020). Key findings from the 'Australians' Drug Use: Adapting to Pandemic Threats (ADAPT)' Study. ADAPT Bulletin no. 1. Sydney: National Drug and Alcohol Research Centre, UNSW Sydney. http://doi.org/10.26190/5efbef7c8d821








Kirby Institute







# Australians' Drug use: Adapting to Pandemic Threats



opioid agonist treatment (OAT) medication (<1%)

\*i.e since March 2020

### Participant Reports of Changes in their Drug Use Pre and Post COVID-19 Restrictions




Cannabis and alcohol use had most commonly increased since the beginning of March (i.e., since COVID-19 restrictions) as compared to before.



MDMA, cocaine and ketamine use had most commonly decreased since the beginning of March (i.e., since COVID-19 restrictions) as compared to before .



Use of pharmaceutical opioids, GHB, benzodiazepines, e-cigarettes & LSD had most commonly remained stable since the beginning of March.





### **DRUG USE BEHAVIOURS**



Most participants continued to receive their drugs in person (76% in Feb 2020 vs 66% past month).



There was a small increase in the proportion of participants who had their illicit drugs delivered to them (36% Feb 2020 vs 41% past month).



There was a small increase in those who did not obtain illicit drugs post March 2020 (4% in Feb 2020 vs 10% in past month).



8% reported injecting any drug since the beginning of March 2020 (10% past year, 16% lifetime)

# HARM REDUCTION (HR) BEHAVIOURS

In response to COVID-19 restrictions (i.e., since March 2020, n=685):



16%

Wiped down drug

packages with

soap/sanitizer

12% Stocked up on prescribed medications



11% Prepared





24% Avoided sharing drug use equipment

36%

Washed hands

before handling

drugs/money



Note: 10% reported engaging in other HR behaviours, and 30% reported engaging in none of the listed HR behaviours.

## DRUG-RELATED HARMS

4% reported an overdose since the beginning of March 2020 (13% past year, 31% lifetime)

### TREATMENT ACCESS & ENGAGEMENT

**Drug Treatment since March 2020** Treatment engagement was low. Of those who answered (n=593):



3%

Had accessed drug treatment in the past four weeks

Tried but were unable to access drug treatment

# Mental health services since March 2020

Of those who answered (n=577):

# 37%

Had accessed help for mental health reasons in the past four weeks

## 8% Tried but were unable to access mental health services










**CHANGES IN HEALTH RATINGS** 

Participants' mental health and physical health ratings in the past month vs February 2020 (pre COVID-19 restrictions)



### Better Stable Worse

NCCRED







# SUMMARY

- The ADAPT sample comprised mostly young, well-educated capital city dwellers. Being a convenience sample, findings from the ADAPT study cannot be considered representative of all people that use drugs.
- Cannabis and alcohol use had most commonly increased relative to before March 2020, while use of MDMA, cocaine and ketamine had most commonly decreased.
- Participants reported engaging in a range of behaviours to reduce the risk of contracting COVID-19 and/or minimise impact of COVID-19 restrictions since March 2020, including washing hands before handling drugs/money and avoiding sharing drug equipment.
- More than half of participants reported poorer mental health in the past four weeks relative to before March 2020, with almost two-fifths reporting that they had accessed help for mental health reasons in the past four weeks.
- A small proportion of the sample reported that they had tried but been unable to access drug treatment and/or mental health services post March 2020.
- It is critical to continue to monitor the impacts of COVID-19 on different populations who use drugs (e.g., through the <u>SuperMIX</u> and <u>IDRS</u> interviews with people who regularly inject drugs).
- Findings from future surveys of the ADAPT sample will be reported on in future outputs.

## ACKNOWLEDGEMENTS

- The participants who contributed their valuable time to share their experiences.
- The Australian Injecting & Illicit Drug Users League (AIVL) for their support and advice in developing the project.
- All those who gave advice and shared information about the project.
- The National Drug and Alcohol Research Centre and the Australian Government Department of Health for funding support.

# FOR UPDATES ON FUTURE OUTPUTS

- Email <u>adaptstudy@unsw.edu.au</u>
- Check out our website at www.adaptstudy.org.au

Follow <u>@NDARCNews</u> or #ADAPTStudy on Twitter Follow ADAPT Study on Facebook

©NDARC, UNSW SYDNEY 2020. This work is copyright. You may download, display, print and reproduce this material in unaltered form only (retaining this notice) for your personal, non-commercial use or use within your organisation. All other rights are reserved. Requests and enquiries concerning reproduction and rights should be addressed to the information manager, National Drug and Alcohol Research Centre, UNSW Sydney, NSW 2052, Australia.





Kirby Institute





